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Early immune anergy towards recall 
antigens and mitogens in patients 
at onset of septic shock
M. Feuerecker1, L. Sudhoff1, B. Crucian2, J.-I. Pagel1, C. Sams2, C. Strewe1, A. Guo1,  
G. Schelling1, J. Briegel1, I. Kaufmann1,3 & A. Choukèr1
The pathology of sepsis is typically characterized by an infection and excessive initial inflammation 
including a cytokine storm, followed by a state of immune suppression or paralysis. This classical view 
of a two peak kinetic immune response is currently controversially discussed. This study was a sub-
study of the randomized clinical Trial SISPCT registered with www.clinicaltrials.gov (NCT00832039, 
Registration date: 29/01/2009). Blood samples from 76 patients with severe sepsis and septic shock 
were incubated for 48 h at 37 °C in vitro with bacterial or fungal recall-antigens or specific mitogen 
antigens within 24 hours of sepsis onset. Recall-antigen stimulation led to a severe dampening of 
normal cytokine release. This immunologic anergy was similarly observed after mitogen stimulation. 
Moreover, patients under hydrocortisone therapy or with lowered arterial oxygen tension had further 
reductions in cytokine levels upon B- and T-cell mitogen stimulation. This investigation reveals an early 
onset of immunoparalysis during sepsis. This immune incompetence in mounting an adequate response 
to further infections includes previously sensitized pathogens, as seen with recall-antigens. Also, 
the immune-suppressive role of hydrocortisone and low PaO2 is highlighted. Aside from early broad-
spectrum antimicrobial therapy, our findings reinforce the need for maximal immunological support 
and protection against further infections at the onset of sepsis.
Sepsis and sepsis-associated disease states are not only an observation in modern medicine, there have long 
been many reports dealing with this particular condition in the past. Sir William Osler (1849–1919) observed 
that patients apparently died from the body’s response to the infection rather than from the infection itself1. His 
observations of the immune system still hold true today, making sepsis a particularly dangerous and tenacious 
disease. At the end of the 20th century, incidence of sepsis has increased annually by 8.7% in the US, peaking 
in the year 2000 at 240.4 per 100,000 inhabitants. Although the in-hospital mortality decreased from 27.8% to 
17.9%, the total number of deaths continued to rise due to the increase in incidence2. Despite all advances in 
modern medicine and antimicrobial therapy, sepsis and in particular septic shock are still the leading causes for 
death in critically ill patients in the United States1,3. Considering sepsis to cause a comparable number of annual 
deaths as acute myocardial infarction4, further research leading to new therapeutic strategies is directly needed.
Besides systemic inflammatory response syndrome (SIRS), which still is the hallmark sign of sepsis, another 
contrary condition in the progression of sepsis is described in the literature. It is associated with an inhibition of 
the immune system, resulting in a lack of response to pathogens, and goes by different names, such as compensa-
tory anti-inflammatory response syndrome (CARS) or immune paralysis5–7. This condition causes a severe sus-
ceptibility to secondary infection and might be responsible for a significant number of deaths in the later phases 
of sepsis. There are different hypotheses concerning this immunosuppressive state. It is assumed that a shift from 
a TH1-dominated initial immune response resulting in excessive inflammation and, subsequently, SIRS, to a 
TH2-dominated anti-inflammatory state might contribute to the development of CARS3. Different works state 
that extensive lymphocyte apoptosis during sepsis progression seems to be, at least in part, responsible for the 
genesis of CARS8. Recent findings suggest that hyperinflammation and hypoinflammation are two concurrently 
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developing processes in sepsis, terming it as mixed anti-inflammatory response syndrome (MARS)6,9. There are 
numerous further theories concerning the pathophysiology of immunosuppression in sepsis, including impaired 
leukocyte recruitment and decreased cell surface protein expression10. After all, the exact pathophysiology of 
sepsis and the accompanying hyperinflammatory and immunosuppressive states are still poorly understood.
To gain better insight into the early phase of septic shock we have recruited patients for the present clinical 
trial. The main focus was to evaluate the patients’ initial immune function shortly after onset of severe sepsis or 
septic shock. This was carried out with a recall-antigen whole blood assay, along with specific innate and adaptive 
immune cell activation assays. We hypothesized a pre-existing global immunosuppression at this time point. 
Moreover, this report looks at the capacity of these assays to detect effects of additional early hydrocortisone (HC) 
treatment as well as the immunosuppressive consequences of hypoxia in this patient cohort.
Results
Study design and demographic data. The immune function study was conducted from June 2011 to 
February 2013 as part of the clinical trial SISPCT11 (www.clinicaltrials.gov: NCT00832039, Registration date: 
29/01/2009). In total, 76 patients with severe sepsis or septic shock were included. An age- and sex matched 
healthy volunteer (HV) control group was recruited between September 2012 and December 2012. No signifi-
cant group differences could be determined based on age, sex, height, body weight and body mass index (BMI) 
(Table 1).
At the time of enrolment, 96.0% (n = 73) of patients received antimicrobial therapy. In 53% (n = 40) of patients, 
pneumonia was identified as the primary focus, followed by intra-abdominal foci (19%, n = 14). Pathogen detec-
tion was achieved in 51% (n = 39) of the cases. Therein 54% (n = 21) were shown to be gram-negative sepsis, 
38% (n = 15) gram-positive and 8% (n = 3) viral. Increased “Simplified Acute Physiology Score II” (SAPS II) 
and “Acute Physiology and Chronic Health Evaluation II” (APACHE II) scores were seen (Table 1). About 95% 
(n = 70) of patients were treated with inotropic or vasopressor medications for an average of 14.2 ± 8.3 h (n = 70) 
at study enrolment. The majority of patients on multiple catecholamines (n = 40) received hydrocortisone 
within the first 24 h (n = 30). The 90-day mortality was 18.7% (n = 14) with a mean survival of 30.6 ± 33.4 days. 
Immediately after patient enrolment, blood was drawn for the study. In mean average this was 14.5 hours (SD 
5.8 hours) after the first symptoms occurred.
Blood Samples. Complete Blood Count (CBC). Almost all patients had abnormal CBC results. 11 patients 
showed leukopenia and 39 patients had leukocytosis (Table 2).
Plasma Inflammation Markers. Except for one patient with a normal C-reactive protein (CRP) value and 
another with normal procalcitonin (PCT), all others had an elevated CRP, interleukin (IL) 6 and PCT (Table 2).
In vitro Recall Antigen and Mitogen Stimulation Assays. Determination of the initial immune function: 
Spontaneous cytokine release in the unstimulated (basal) assay showed significantly lower levels of IFN-γ and 
IL-2 in septic shock/ septic patients (SS). After stimulation with recall antigens, patients had significantly lower 
pro-inflammatory cytokine levels (interleukin (IL)-2, interferon (IFN)-γ, tumor necrosis-factor (TNF)-α) com-
pared to healthy volunteers (HV), irrespective of the type of antigen used (bacterial, fungal) (Fig. 1). Cell specific 
stimulation assays with pokeweed mitogen (PWM), lipopolysaccharide (LPS), phorbol 12-myristate 13-acetate 
(PMA)/Ionomycin, and CD3/CD28 (Fig. 2) also revealed a significant reduction in pro-inflammatory cytokine 
Patient and general variables Patient Group
Healthy 
Volunteers 
Group p
Age [yrs]a 60.9 ± 16.6 55.5 ± 12.5 0.15b
Body weight [kg]a 83.9 ± 24.2 (n = 75) 82.6 ± 19.0 0.22
c
Height [cm]a 171.3 ± 9.5 (n = 73) 175.0 ± 8.0 0.94
b
Body Mass Indexa 28.6 ± 8.4 (n = 73) 27.0 ± 6.2 0.57
b
Sex (male/female) 41/35 8/3 0.24d 0.34e
Glasgow Coma Scale (GCS)a 6.5 ± 5.2 (n = 76) 15
Acute Physiology And Chronic Health Evaluation II 
(APACHE II)a
27.4 ± 8.4 
(n = 74) Not assessed n.a.
Simplified Acute Physiology Score (SAPS II)a 65.7 ± 16.2 (n = 74) Not assessed n.a.
Ventilation (none/non-invasive/invasive) 13/10/53 11/0/0 n.a.
Vasopressors (yes/no) 70/6 0/11 4.42e−10,c
Antimicrobial therapy (yes/no) 73/3 0/11 4.87e−11,c
Hydrocortisone (yes/no) 41/35 0/11 <0.001c
Table 1. Comparison of general patient and healthy volunteers data, including important Intensive Care Unit 
scores and therapy variables. aValues are mean ± SD; bMann-Whitney U test, ct-test, dChi Square test, eFisher’s 
exact test; n.a. = not applied.
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release (IL-2, IFN-γ, TNF-α) in comparison to HV. Differences between groups after LPS stimulation, which 
mimics bacterial endotoxins and assesses the innate immune response, were less pronounced but reached statis-
tical significance for Interleukin 1β and TNF-α. Anti-inflammatory interleukins (IL-4, IL-5, IL-10) were signifi-
cantly lower in sepsis patients and close to the lowest detection limit of the assays. Statistically significant group 
differences for IL-10 however were only observed after stimulation with soluble antibodies to both CD3 and 
CD28, given a low significance level (p < 0.05). No differences were observed between male vs. female patients 
(n.s.).
Disease severity classification systems and the stimulation assays: In order to correlate with disease severity, we 
used SAPS II and APACHE II. Correlation of SAPS II and APACHE II values with the 90-day mortality showed 
no statistically significant effect although a tendency towards a positive correlation was present (Supplemental 
Table 1 and Fig. 3).
An increase in disease severity, represented by SAPS II and APACHE II scores, was associated with an 
impaired TNF-α response both after bacterial antigen (Fig. 3A,B) as well as PWM stimulation (Fig. 3C,D).
Immune answers of septic patients with or without hydrocortisone: In patients with refractory septic shock, 
a daily dose of 200–300 mg of hydrocortisone is recommended12. In our patient collective, 43 patients (56.6%) 
received hydrocortisone (HC) during the first 24 h of admission to the intensive care unit (ICU). We compared 
this group to the patients who received no hydrocortisone within this time period with respect to assays cytokine 
release. Analysis of the two groups revealed no significant differences in the CBC, but the disease severity scores 
varied significantly (SAPS II: HC: 72.7 ± 14.9, n = 43; no HC: 55.9 ± 12.8, n = 31; APACHE II: HC: 31.0 ± 7.4, 
n = 43; no HC: 22.4 ± 7.1, n = 31). Patients on HC therapy had higher IL-6 levels compared to the other group 
(HC: 29854 ± 93424 pg/ml, n = 35; low HC: 4906 ± 16335 pg/ml, n = 27; Mean ± SD; Mann- Whitney- U test, 
p = 0.058). Patients receiving hydrocortisone showed a highly significant suppression of TNF-α in the PWM 
assay (Fig. 4A, p < 0.001) and IL-1β release in the LPS assay (Fig. 4B, p < 0.01). This significant difference was 
present although the stimulated cytokine responses in all septic patients were enormously reduced as compared 
to the healthy volunteers.
Hypoxemia and immune response: Using the normal range of PaO2 when breathing room air (PaO2 
80–100 mmHg13), we classified the subgroups as “hypoxemic” patients (PaO2 < 80 mmHg) or “normoxemic” 
patients (PaO2 80–100 mmHg)14. Figure 5 shows correlations between PaO2 and cytokine release in the assays 
stimulated with PWM and LPS, respectively. In both assays, supernatant cytokine concentrations (TNF-α, IL-1β) 
in the “normoxemic” group were higher than those in the hypoxemic group. APACHE II and SAPS II showed 
statistically similar scores irrespective of the PaO2 status.
Receiver operating characteristics Initiation of renal replacement therapy: For receiver operating characteris-
tic (ROC)-analyses using the endpoint “initiation of renal replacement therapy (RRT) during stay on ICU”, the 
cytokine assay read-outs from PWM TNF-α and LPS IL-1β as well as disease severity classification systems SAPS 
II and APACHE II showed similar results, with high statistical significance (Fig. 6).
Discussion
Testing blood samples from septic patients with a new in vitro recall antigen whole blood assay15 and 
immune-cell-specific and unspecific mitogenic stimulation assays revealed, that the human immune system is in 
a paralyzed state at the onset of sepsis. This blunted immune response from monocyte, T- and B-cell activation 
can account for the almost entirely extinct cytokine release upon bacterial and fungal recall antigen stimula-
tion. These responses and the immunologic memory to such re-call antigens is one of the key adaptive immune 
competencies of the host when re-exposed to known pathogens. This old preserved mechanism seems entirely 
suppressed at the onset of sepsis and might be considered as one explanation for the long lasting immune com-
promised state and high morbidity.
Septic patients Standard Value Mean ± SD Range
Complete blood count (CBC)
Leukocytes [G/l] 4.5–10.5 14.6 ± 10.6 ↑ 0.8–46.8
Erythrocytes [T/l] 4.2–5.1 3.5 ± 0.7 ↓ 2.3–5.5
Hemoglobin [g/dl] 12.0–16.0 10.7 ± 2.3 ↓ 7.0–18.0
Hematocrit [%] 36.0–46.0 31.3 ± 6.4 ↓ 20.9–50.7
Thrombocytes [G/l] 150–400 191.6 ± 97.6 32–571
Mean Corpuscular Volume (MCV) [fl] 79.0–92.0 89.8 ± 6.3 67.6–104.0
Mean Corpuscular Hemoglobin (MCH) 
[pg] 26.5–32.5 30.1 ± 2.4 21.8–35.6
Mean Corpuscular Hemoglobin 
Concentration (MCHC) [g/dl] 32.0–36.0 33.6 ± 1.5 29.8–36.7
Plasma inflammation markers
CRP [mg/dl] ≤0.5 20.7 ± 14.6 ↑ 0.3–66.5
Interleukin-6 [pg/ml] ≤5.9 18989.6 ± 71652.2 ↑ 26–499,000
Procalcitonin [ng/ml] ≤0.1 16.9 ± 25.5 ↑ 0.1–105.0
Table 2. Complete Blood Count (CBC) and Plasma inflammation marker. Deviation from standard values are 
marked bold. Data are mean ± SD; n = 51–68.
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Figure 1. Patients versus control group in unstimulated assay and after stimulation with recall antigens. 
SS: severe sepsis/septic shock patients, Basal: unstimulated test assay, Bacteria: bacterial antigen mixture, 
Fungi: fungal antigen mixture. Blood samples were taken subsequently to study enrolment (SS) or at a time 
of subjective physical well-being (control group), respectively. In boxplots, boxes show the median and 
interquartile range (IQR), whiskers represent the 10th and 90th percentile. Statistically significant differences 
(Mann-Whitney Rank Sum Test) are indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001. y-axis: 
logarithmic scale.
Figure 2. Patients versus control group after stimulation with PWM, PMA, CD3/28 and LPS. PWM: Pokeweed 
mitogen, LPS: Lipopolysaccharide, PMA-I: Phorbol myristate acetate and Ionomycin, CD3/28: Cluster of 
Differentiation 3/28, SS: severe sepsis/septic shock patients. Blood samples were taken subsequently to study 
enrolment (SS) or at a time of subjective physical well-being (control group), respectively. In boxplots, boxes 
show the median and interquartile range (IQR), whiskers represent the 10th and 90th percentile. Statistically 
significant differences (Mann-Whitney Rank Sum Test) are indicated as follows: *p < 0.05, **p < 0.01, 
***p < 0.001. Y-axis: logarithmic scale.
www.nature.com/scientificreports/
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These findings expand our understanding of the consequences of severe immune dysfunction, frequently 
described as “immunoparalysis”16, by using this battery of ex vivo stimulation assays. Furthermore, this clinical 
trial demonstrates that patients who received stress doses of hydrocortisone (HC) had even more suppressed 
immune responses. Immune suppression in septic shock patients was further aggravated when the degree of 
oxygenation resulted in PaO2 levels lower than 80 mmHg.
Early on in the development of sepsis, it is classically described that an initial excessive inflammatory state 
occurs, typically known as a cytokine storm3. The entire organism appears to be in an ultimate inflammatory state 
with pro-inflammatory processes adding up, resulting in tissue injury, organ failure and further inflammation. 
Pro- and anti-inflammation are two concurrently developing processes emerging early in these pathophysio-
logic processes9,17,18, which are most commonly referred to as mixed antagonist response syndrome (MARS). 
In the literature, there is relatively little information on the exact kinetics of septic conditions and inflammatory 
responses. Tamayo et al.17 described that pro- and anti-inflammatory responses are simultaneously regulated in 
the first onset of sepsis. Herein, plasma levels of IL-6 and IL-8 were up-regulated but also IL-10. Murine sepsis 
Figure 3. Relationship between disease severity and TNF-α release in Bacteria and PWM assay. TNF-α 
release from whole blood was correlated with quartile groups for disease severity as measured by SAPS II (A,C) 
and APACHE II (B,D) disease severity classification systems. Panels A and B show hereby stimulations with 
bacterial antigen mixtures, Panels C and D with Pokeweed mitogen assay. Statistically significant differences 
(One-way ANOVA on RANKS followed by Dunn’s test) are indicated *p < 0.05.
www.nature.com/scientificreports/
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models based on cecal ligation and puncture (CLP) showed that the systemic inflammatory response represented 
by elevated levels of pro-inflammatory cytokines in the blood plasma began to emerge within 2–8 hours after the 
insult, depending on the individual cytokine19. Anti-inflammatory processes are assumed to begin within the first 
24 hours in human sepsis20.
Figure 4. Relationship between hydrocortisone administration and cytokine release. Patients were allocated to two 
groups (Hydrocortisone (HC) or no HC) for comparison of stimulated cytokine release. (A) TNF-α in supernatants 
of whole blood stimulated with PWM. (B) IL-1β in supernatants of LPS stimulated whole blood. Statistically 
significant differences (Mann-Whitney Rank Sum Test) are indicated as follows: **p < 0.01, ***p < 0.001.
Figure 5. Relationship between PaO2 and cytokine release. Patients were allocated to groups regarding 
their arterial partial pressure of oxygen (PaO2) for comparison of stimulated cytokine release: hypoxemia 
(PaO2 < 80 mmHg) and normoxemia (PaO2 80–100 mmHg). (A) TNF-α measured after stimulation with PWM. 
(B) IL-1β measured after stimulation with LPS. Statistically significant differences (Mann-Whitney Rank Sum 
Test) are indicated *p < 0.05.
www.nature.com/scientificreports/
7ScIeNTIfIc REPORTS |  (2018) 8:1754  | DOI:10.1038/s41598-018-19976-w
Overall immune response in sepsis. The here observed ambivalent behavior of high IL-6 serum levels 
and corresponding low whole blood assay responses can be attributed to the finding that in subacute phases of 
infectious conditions, the resulting “cytokine storm” is not a physiologic reaction to pathogens, but rather a mas-
sive liberation of so-called damage-associated molecular patterns (DAMPs)21. The degree of tissue injury and thus 
the disease severity, as seen by a marked rise in pro-inflammatory markers such as CRP and IL-6, is negatively 
correlated with the whole blood response to immunologic stimulants. This results in a heightened susceptibility 
to secondary infections and thus late-phase mortality. The critical players include all immunologic cells and espe-
cially cells with leukocytic origin. Regardless of leukocyte differentiation, the cell count in itself already indicates 
an upset in the immune response. Unsurprisingly, our patients with moderate leukocytosis had the best immune 
response, whereas both leukopenia as well as severe leukocytosis were associated with increased immune dys-
function. This suggests that higher disease severity is related to the lowest whole blood assay responses.
Furthermore, when correlating assay response in the latter patient group with SAPS II and APACHE II, this 
relation between significantly impaired immune function with disease severity scores was demonstrated again. 
Both scores incorporate physiologic parameters which are typically deranged in cases of organ failure and tissue 
injury22,23. These results also substantiate the aforementioned relationship to inflammatory parameters, that our 
assays were able to help further quantifying disease severity from an immunologic standpoint.
Figure 6. ROC curves for the endpoint‘‘RRT during ICU stay” ROC-curves for (A) whole blood response, 
(B) established parameters used in sepsis and (C) different combinations of markers referring to (A and B) 
regarding the endpoint “initiation of RRT during ICU stay”: ROC: Receiver operating characteristic curve, all 
markers combined: combination of PWM stimulated TNF-α release, LPS stimulated IL-1β release, SAPS II, 
APACHE II and serum IL-6.
www.nature.com/scientificreports/
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Pan-immune cell paralysis?! The battery of assays display a lack of adequate immune responsiveness in 
almost all major leukocyte lineage cells, stimuli and antigens used. Recall antigen responses to bacterial toxoids 
and fungal antigens as well as to polyclonal B- and T-cell activation were highly suppressed and almost entirely 
blunted. Selective activation of T-cells via co-receptor CD3 and the co-stimulant CD28 was also strongly sup-
pressed in septic patients. In light of the mechanisms of Ca++-ionophore (Ionomcyin)/PMA action which leads 
to reduced T cell activation and cytokine synthesis, a reduction in the signaling capacity of the proteinkinase C 
(PKC) pathway can be anticipated. Moreover, activation of CD14/TLR4 from innate immune cells (monocytes 
and granulocytes24) through the endotoxin stimulus LPS led to a strong and significant reduction in the release 
of several key cytokines (IL-1β, TNF-α). This activation may be linked to the PKC pathway and its isoforms25 
as a key cellular target potentially explaining this cell-mediated immunologic anergy. The role of PKC isoforms 
in separated cell subsets could not be further elucidated using complementary assays due to the limited blood 
volumes available.
The highly suppressed cytokine responses to the strong mitogenic (PWM) and receptor specific stimuli (LPS) 
were still in a well detectable range which allowed for comparisons of either activation or further suppression in 
sub-cohorts of patients. PWM and LPS assay results were identified as suitable and included in further analyses 
for the role of HC, oxygenation (Figs 4 and 5) and other Receiver Operating Characteristic (ROC) findings (see 
supplemental Table 1 and supplemental Fig. 3).
Effects of hydrocortisone and oxygenation. A highly significant suppression of pro-inflammatory 
cytokine release was observed in patients receiving stress doses of HC. Considering the clinical indications as 
well as effects of HC therapy, it is in many ways a double-edged sword. The genomic effects of HC results in 
immunosuppression which impairs the whole blood assay response and further dampens the immune cells per-
formance in raising a TH1 response. One must take into account that according to clinical guidelines, applica-
tion of HC should be restricted to patients in refractory septic shock, where hemodynamic stability cannot be 
restored despite adequate fluid resuscitation and vasopressor use12,26. Within our patient population, this applies 
to patients in the most fulminant phase of septic shock and defines a high severity of the septic state. Therefore, 
the observed immune function differences between the two sub-groups (low and high HC) could be also due to 
patient selection as indicated in the administration of hydrocortisone in septic shock.
Hypoxemia can impact the immune response, as shown by our and other studies27. Hypoxia-induced 
anti-inflammatory mechanisms are mediated by the A2 adenosine receptor (A2AR)28, HIF and other path-
ways29,30. The anti-inflammatory effects are enabled by various mechanisms such as the inhibition of oxidative 
burst and a reduction in platelet activation minimizing microvascular occlusion; especially through a reduc-
tion in pro-inflammatory cytokines being released (mainly TNF-α or IFN-γ) and an increased release of 
anti-inflammatory cytokines such as IL-10 or IL-4, suggesting a shift of the lymphocyte TH1/TH2-equilibrium 
towards the TH2-pathway31,32. In the here presented study, we observed a greater immune suppressive response 
in the hypoxemic patient population. The disease scores and elevated levels of serum lactate as a surrogate param-
eter for hypoxia were used to identify the state of hypoxia. The blood assays show a significant attenuation of the 
TH1-responses (IL-1β, TNF-α) when PaO2 was below 80 mmHg as compared to normoxemic conditions. The 
TH2 responses were almost uniformly low and close to the detectable threshold of the respective cytokine assays 
(e.g. IL-10, PMA stimulation, PaO2 < 80 mmHg: 11.4 ± 16.0 pg/ml), suggesting that a TH2 shift and the role of 
HC or oxygen play a more significant role than the dampening of TH1 responses.
Role of the immune response in the prediction of renal replacement therapy (RRT). Acute renal 
failure (ARF) is a common complication of severe sepsis or septic shock. It is not only an indicator of disease 
severity, but also an independent risk factor for death, occurring in as often as 41% severe sepsis and septic shock 
cases in a 2007 prevalence study carried out in German ICUs33. ARF and the initiation of renal replacement 
therapy are predictors of unfavorable disease progression and mortality. Sepsis survivors are at high risk for suf-
fering from chronic kidney disease34. While considering the endpoint “initiation of renal replacement therapy”, 
the immune dysfunction of RRT patients became apparent. ROC analyses using TNF-α and IL-1ß from the in 
vitro assays after stimulation with PWM and LPS can sensitively and specifically predict need for RRT, as good as 
the widely used SAPS II, APACHE II scores. Combining these immune functional parameters with Serum IL-6, 
SAPS II and APACHE II, one could generate a useful predictive value in the ROC for RRT with high specificity 
and sensitivity. The predictive value exceeds that of the conventional parameters in use today. These findings show 
that immune responses to strong immunologic stimuli (PWM, LPS) might be an additional immune functional 
tool which can help predicting the need for RRT when combined with established markers and scoring systems 
in sepsis patients. Parameters on its own, even when a strong positive correlation can be established, are not suf-
ficiently powerful predictors and should be aggregated for better utility. This could be used clinically to identify 
patients at high risk for receiving RRT and to adjust treatment strategies early.
Consequences. Hygiene, reverse isolation and quarantine. Our data demonstrate that in the very first 
moments after septic shock onset, immune competence is severely compromised and adaptive immune system 
responses seem almost non-existent. Liu et al.35 were recently able to show in 35,000 sepsis patients that with 
every hour of delay in antibiotic treatment within the recommended 6 hour window, mortality increases. Patients 
suffering from critical illness and associated immune suppression are also easy targets for secondary infections 
from viruses and opportunistic pathogens36,37. More direct anti-infective therapy does not seem effective when 
dealing with this issue in sepsis. As soon as one organism is successfully eliminated with antibiotics, antimycotic 
or virostatic agents, another one not covered by the first round of medications or by the immune system often 
leads to a superinfection36, and many of these pathogens tend to be multidrug-resistant37.
www.nature.com/scientificreports/
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In order to minimize the risk of acquiring an opportunistic infection, patients benefit from strict compliance 
with infection prevention and control38. More efforts should be invested in creating better awareness for this issue 
amongst medical personal. Moreover, temporary reverse isolation and quarantine, typical in other immune sup-
pressed patients i.e. organ transplantation post-op, could have beneficial effects. Although a recent review showed 
that noncompliance resulted in a paradoxical increase in adverse events38.
Restriction of hydrocortisone administration. Administration of hydrocortisone in sepsis should be considered 
on a case by case basis, since HC can further weaken the immune response. The effects of both high-dose as 
well as low-dose corticosteroids were examined previously in septic patients, none of which showed conclusive 
improvement in survival39,40. There is evidence that an earlier reversal of shock may be accomplished by corticos-
teroid application40,41. As such, corticosteroid administration in current guidelines is restricted to cases of refrac-
tory septic shock that does not respond adequately to fluid resuscitation and vasopressor therapy12,26. Our data on 
the additional immunosuppressive effects is in line with current recommendations that the use of corticosteroids 
in sepsis should be limited to refractory cases.
Immune function monitoring and modulation. Severe immunosuppression at the onset of sepsis as seen in this 
trial and increasingly being discussed in recent literature suggest the potential role of immune modulatory thera-
pies such as GM-CSF or IFN-γ42. One of the latest reviews on this topic concluded that in the absence of deleteri-
ous side effects from GM-CSF administration in sepsis patients, multiple clinical benefits such as rapid recovery 
from infection, reduced length of hospital stay and decreased need for mechanical ventilation were seen43. The 
immune cell expansion and other potential immune stimulatory therapies in sepsis are compelling concepts. 
With increasing evidence that patient deaths are a consequence of the immunosuppressive state, immune enhanc-
ing drugs could become the next milestone in sepsis therapy16.
Conclusion
The stimuli used in these whole blood immune assays are based on the principles of re-call antigen responses, 
specific T and B cell answers or innate cell activation. Taken together it reflects the body’s ability to mount an 
immune response against a broad spectrum of pathogens, showing anergy and immune-paralysis early on in sep-
sis. This suppressed state of the immune system requires immediate additional protection against opportunistic 
infections including an early anti-infective treatment, proper hygiene measures and reverse isolation or quaran-
tine. The roles of HC therapy and PaO2 values should also be considered. The broadly used early hydrocortisone 
application in septic shock should be carefully evaluated on a case by case basis. This study reveals that further 
research needs to be done to establish a profound marker and immune functional assay – directed therapy.
Limitations and Considerations
The focus of this investigation was the clinical evaluation of the immune competence upon further distinct 
immune stimulation in whole blood. Due to recruitment time point and the overall clinical study setup (includ-
ing strict blood volume limitations) it was not possible to test for specific cell subsets, cell numbers or cell viability 
under all conditions. To overcome some concerns, in vitro experiments were carried out to test for the effects of 
the assay incubation on the apoptosis and necrosis of the cytokine producing cells. Here CD3, CD4, CD8 and NK 
cells as well as granulocytes revealed only a moderately increased immune cell apoptosis and necrosis after 48 h 
assay incubations (e.g. range of necrosis was ~1% in non-stimulated T-cells and up to 10% in PWM stimulated 
assays).
Moreover, data as presented on this clinical study were analyzed and presented as they were collected, and no 
extreme outlier exclusion or other statistical tools were applied in order to evaluate the strength and weaknesses of 
this immune assay approach test to function despite the huge inter-individual pattern. The authors are aware that 
patients with severe sepsis are a very heterogeneous group and preexisting co-morbidity impacts the longterm 
outcome as Mansur et al. described44. As our study focused primarily on the onset of sepsis, co-morbidities were 
not taken into calculations.
Furthermore, the here presented control group is small but data of the controls are in the margins of what 
other control experiments in healthy male and female have shown. This presented control group was run in the 
study period, with the same operators, assay procedures (incl. reagent’s lot etc.) and subsequent analyses.
Samples from healthy volunteers were taken venously and from an arterial line in the septic patients which 
may have led to some bias. Any kind of inflammatory or systemic diseases were excluded in the healthy sub-
jects and no relevant difference between arterial and venous blood shall be hence anticipated. Moreover, in the 
light of this knowledge and due to the very strict handling of ethical boards to minimize risks to volunteers, an 
arterial draw was not possible in the healthy subjects as it seemed hardly justifiable due to an increased risk of 
potential severe side effects such as malperfusion or necrosis. The blood draw from an arterial line was performed 
in septic patients to avoid any contamination or bias (dilution) as if blood would have been taken from central i.v. 
line, which is used otherwise for infusion therapy or drug administration or parenteral nutrition. Interestingly, 
several publications also addressed the question e.g. if proteins or functions of blood components change in 
arterial or venous blood. Kelly et al.45 were able to show that in patients with COPD, biomarkers were comparable 
in arterial and venous blood samples. Some other reports46,47 describe in severely sick patients some differences 
indicating some advantage to the draw of blood from the arterial line in inflammatory lung disease, but however 
still, these reports overall judge a similar value of venous to arterial blood. Fernández-Serrano et al.46 report some 
preference to arterial blood when lung sick people are investigated. In the current study on sepsis the lung was 
often affected and one might anticipate-since we have drawn arterial blood-that the “better sample” was collected 
in the study population. Overall a bias in the immune parameters analyzed just because of the different sites of 
blood draw in healthy volunteers or septic patients, respectively, can be excluded to a large extent.
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Methods
Study design. The present immune function study was part of a prospective, randomized, multicenter clinical 
trial named “Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in 
Severe Sepsis” (SISPCT, NCT00832039)11,48.
Informed Consent. Ethical study approval for additional experiments performed at our center was obtained as 
a local amendment to the approved SISPCT study [Eudra-CT-Nr. 2007-004333-42] from the ethical board of the 
University of Jena.
After positive patient screening, written informed consent signed by the patient or by the legal representative 
had to be present for enrolment. In case of withdrawal, the patient was immediately excluded from the study and 
no further follow-up was performed.
All reported experiments and methods were approved by the ethical board of the University of Jena and 
were in accordance with the relevant guidelines and regulations. The respective experiment protocols were also 
approved by the ethical committee of the University of Jena.
Data recording. In addition to the acquisition of data on demographics, biometrics, past medical his-
tory and clinical and laboratory findings, the disease severity classification scores Simplified Acute Physiology 
Score II (SAPS II)22 and Acute Physiology And Chronic Health Evaluation II (APACHE II)23 were calculated. 
Furthermore, the Glasgow Coma Scale (GCS) was assessed. The control group was small but based on our previ-
ous experiences with other healthy volunteers it was in the margins of what other control experiments in healthy 
male and female have shown and it was hence considered a valid size, also since it was matched to the expected 
age and gender composition of the studied patients at the time of the study. In the volunteers, we have been also 
using the same lot of reagents/antigens and the exactly same methods and operators to try minimizing the risk of 
a methodologic bias. All recorded data and analyses were anonymized and stored in a database (SPSS® Statistics 
21, IBM Corp., New York City, NY, USA).
Study specific blood Sample Collection. Immediately after patient enrolment, 9 ml blood was collected 
from an in situ arterial line in lithium-heparinized tubes (Sarstedt, Nümbrecht, Germany). In the control group, 
blood was collected by venipuncture of a cubital vein.
Blood Processing. Complete Blood Count (CBC): Erythrocyte, leukocyte and platelet count as well as hemoglo-
bin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean corpuscular 
hemoglobin concentration (MCHC) were assessed upon admission as standard at the intensive care unit (ICU) 
(Institute of Laboratory Medicine, University of Munich, Germany).
Plasma Inflammation Markers. C-reactive protein (CRP), interleukin-6 and procalcitonin (PCT) were routinely 
assessed upon ICU admission and measured according to standard procedures (Institute of Laboratory Medicine, 
University of Munich, Germany).
In vitro Recall Antigen and Mitogen Stimulation Assays. Immediately following sample collection, 400 µl of 
whole blood were transferred into assay tubes prefilled with DMEM (Dulbecco´s Modified Eagle’s Medium 
Nutrient Mixture F-12 HAM, Sigma-Aldrich, Steinheim, Germany) and the different stimulants, as previously 
described15. The in vitro recall antigen and mitogen stimulation assay tubes contained DMEM only or DMEM and 
either a bacterial recall antigen mixture containing Diphteria-, Tetanus- and Pertussis-toxoid or a fungal antigen 
mixture containing Candida-Lysate and Trichophyton-Lysate. Additionally, the following mitogens were used: 1) 
Pokeweed mitogen (PWM), a strong immune activator, induces mitosis in T and B lymphocytes in a non-receptor 
specific fashion49,50; 2) Phorbol-12-myristate 13-acetate (PMA/Ionomycin), an unspecific activator of Protein 
kinase C (PKC)51 affecting multiple cell types52 but is also reported as a pan-specific activator of B-cells53 and 
mitogen for T lymphocytes54; 3) CD3/28 mixture, which activate T cells via the T cell receptor (CD3) and the cell 
receptor (CD28), CD28 provides, via binding to antigen presenting cell, costimulation for T cell activation55; 4) 
lipopolysaccharide (LPS), targets the innate pathways via CD14 cell surface receptors and Toll like receptor (TLR) 
4 signaling cascades56.
Incubation time was 48 h at 37 °C. The supernatant was subsequently transferred into Eppendorf tubes and 
immediately frozen at −80 °C for future cytokine analyses. Frozen supernatants were measured after thawing 
in a blinded fashion by Luminex xMAP® technology (Bioplex®) with commercially available reagents from 
BioRad-Laboratories Inc. (California, USA) according to the manufacturer´s guidelines. The concentrations of 
the pro- and anti-inflammatory cytokines were analyzed (pg/ml).
Statistical analyses. In order not to distort raw data, but to fully illustrate the variability of extreme 
responses and to investigate the effects under real clinical conditions, no outlier analysis was performed and all 
data in this study cohort was kept for analysis. After testing for normal distribution, data were analyzed either by 
Student’s T-test, Mann-Whitney Rank Sum Test or One-way analysis of variance (ANOVA) on ranks followed by 
Dunn´s post-hoc test. Correlation analyses were performed using Pearson’s correlation coefficient or Spearman 
rank-order correlation coefficient, dependent on presence of a normal distribution. All p-values were calculated 
in a two-sided manner and statistical significance was set at a p-value of 0.05.
For better comparability of non-normally distributed data, variable values were divided into specific groups 
(indicated in the individual charts) or four quartile groups, with the 25th, 50th and 75th percentile representing 
the cut-off values for group allocation.
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The predictive value of the in vitro cytokine release of TNF-α, IFN-γ and IL-2 after PWM challenge in patients 
receiving extracorporeal renal replacement therapy (RRT, dialysis) while in the ICU was further assessed alone 
or in combination with other markers of disease severity under a receiver operating characteristic (ROC) curve. 
ROC curves were applied to obtain cut-off values for sensitivity and specificity for the respective cytokines as well 
as the need for dialysis.
Results are expressed as means ± SD in tables and as boxplots in graphs. Boxes show the median and inter-
quartile range (IQR), whiskers represent the 10th and 90th percentile. Data are plotted and were statistically 
analyzed using IBM SPSS® Statistics 21 as well as SigmaPlot 11.0 (Systat Software Inc., San Jose, California, USA).
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